immunotherapy

Provectus Biopharmaceuticals Announces Acceptance of Pharmaceutical-Grade Rose Bengal Sodium Abstract for Poster Presentation at 2024 Society for Investigative Dermatology (SID) Annual Meeting

Preclinical Research on Full-Thickness Cutaneous Wound Healing KNOXVILLE, TN, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or…

10 months ago

Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations

COPENHAGEN, Denmark, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio…

10 months ago

Umoja Biopharma Announces Appointment of Britton Russell as Chief Financial Officer

Britton Russell Britton Russell, Chief Financial Officer, Umoja Biopharma SEATTLE,, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., (Umoja),…

10 months ago

G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today…

10 months ago

Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

Trial will evaluate the effect of this combination therapy on minimal residual disease LAWRENCEVILLE, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE)…

10 months ago

Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research

Conference In Dublin, Ireland on February 27 - 29, 2024Focuses on How to Bring Basic Science Discoveries to the Clinic…

10 months ago

ABVC’s New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars

FREMONT, CA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing…

10 months ago

LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI

Agreement Focuses on Combining LIXTE’s LB-100 with Various Innovative Cancer Immunotherapies PASADENA, CA, Feb. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE…

10 months ago

ASTCT to Present Distinguished Honors at the 2024 Tandem Meetings

CHICAGO, IL / ACCESSWIRE / February 22, 2024 / American Society for Transplantation and Cellular Therapy® (ASTCT) presents top awards…

10 months ago